Literature DB >> 10980886

Medical treatment of hypertrophic cardiomyopathy.

M V Sherrid1, D Gunsburg, A Sharma.   

Abstract

Current medical therapy of hypertrophic cardiomyopathy (HCM) is tailored to relieve symptoms of exercise intolerance, angina, or syncope. In recent years, new concepts in the pathophysiology of HCM have evolved. These concepts underlie our medical therapy and are discussed first in this review. Subsequently, the agents available for the medical treatment of HCM are discussed, along with a practical strategy for rapid medical reduction of outflow gradients. The mechanism of benefit of negative inotropes for obstruction is described, and newer agents under investigation are discussed. Finally, antiarrhythmic therapy for troubling atrial and ventricular arrhythmias is considered.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10980886     DOI： 10.1007/s11886-000-0012-7

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  25 in total

Review 1.  Effect of disopyramide on left ventricular pressure gradient in hypertrophic obstructive cardiomyopathy in comparison with propranolol--a case report.

Authors:  T Tokudome; K Mizushige; T Ueda; S Sakamoto; H Matsuo
Journal:  Angiology       Date:  1999-04       Impact factor: 3.619

2.  Hypertrophic cardiomyopathy: is there a role for amiodarone?

Authors:  K Prasad; M P Frenneaux
Journal:  Heart       Date:  1998-04       Impact factor: 5.994

3.  Effects of diltiazem on myocardial perfusion abnormalities during exercise in patients with hypertrophic cardiomyopathy.

Authors:  H Sugihara; Y Taniguchi; K Ito; K Terada; K Matsumoto; N Kinoshita; A Azuma; Y Ushijima; T Maeda; M Nakagawa
Journal:  Ann Nucl Med       Date:  1998-12       Impact factor: 2.668

4.  Effects of cardiac versus circulatory angiotensin-converting enzyme inhibition on left ventricular diastolic function and coronary blood flow in hypertrophic obstructive cardiomyopathy.

Authors:  M Kyriakidis; F Triposkiadis; J Dernellis; A E Androulakis; P Mellas; G A Kelepeshis; J E Gialafos
Journal:  Circulation       Date:  1998-04-14       Impact factor: 29.690

5.  Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status.

Authors:  D R Rosing; K M Kent; B J Maron; S E Epstein
Journal:  Circulation       Date:  1979-12       Impact factor: 29.690

6.  Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide.

Authors:  C Pollick
Journal:  N Engl J Med       Date:  1982-10-14       Impact factor: 91.245

7.  Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy.

Authors:  M V Sherrid; G Pearle; D Z Gunsburg
Journal:  Circulation       Date:  1998 Jan 6-13       Impact factor: 29.690

8.  Effects of octreotide in patients with hypertrophic obstructive cardiomyopathy.

Authors:  E Demirtaş; C Sağ; H Kurşaklioğlu; M Uzun; T Uzbay; H F Töre; S Köse; C Genç; D Demirkan
Journal:  Jpn Heart J       Date:  1998-03

9.  Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume limitation, heart rate, and diastolic filling characteristics.

Authors:  S S Lele; H L Thomson; H Seo; I Belenkie; W J McKenna; M P Frenneaux
Journal:  Circulation       Date:  1995-11-15       Impact factor: 29.690

10.  Effects of intravenous disopyramide on coronary hemodynamics and vasodilator reserve in hypertrophic obstructive cardiomyopathy.

Authors:  M Hongo; T Nakatsuka; H Takenaka; M Tanaka; N Watanabe; Y Yazaki; M Sekiguchi
Journal:  Cardiology       Date:  1996 Jan-Feb       Impact factor: 1.869
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.